Seroprevalence of SARS-CoV-2 in Mazandaran province, Iran

Seroprevalence of SARS-Cov-2 Virus Infection In Kermanshah, Iran: A Population-based Cross-Sectional Study

“…In the present study, a geographical variation was observed in estimating the seroprevalence, which ranged from 2.3 to 61.6%. Our seroprevalence estimate was less than that reported from Semnan (19.3%, 95% CI, 14.0-26.7) in late June 2020 [14] and more than Mazandaran's 15.26% (95% CI: 12.97%-17.79%) in May 2020 [15]. Between April 17th and June 2nd, 2020, in a large and population-based seroprevalence study using obtained sera samples from 5372 individuals with a high risk of exposure to SARS-CoV-2 and 3530 individuals from the general population in 18 cities in 17 Iranian provinces, adjusted seroprevalence was estimated 20% (18.5-21.7) and 17.1% (95% CI 14.6-19.5) ranged from 72.6% (95% CI: 53.9-92.8) to 1.7% (95% CI: 0•0-6•0), respectively [16].…”

“…Z: for 95% confidence level is 1.96 P: Prevalence of positive COVID-19 based on the results of previous seroepidemiological studies in Kermanshah (15), which was 15%. d: d is the absolute precision, also called the margin of error, which was taken into account in a study of one-quarter of the prevalence, which was 0.0157.…”

“…The detection of SARS-CoV-2 specific IgG and IgM in blood serves as a method for determining whether the individual has been infected recently (IgM) or earlier (IgG); IgM usually increases after seven days of infection before increasing IgG. IgG is a longer-lasting antibody which develops 15 to 30 days after the onset of infection [11,15]. Notably, several studies have reported that approximately 38 to 48% of the population with seropositivity had no symptoms of Covid-19 [16 -18].…”